期刊文献+

肝硬化患者自发性腹膜炎后肾功能的变化与预后的关系 被引量:5

The Relationship between the Changes in Renal Function and Prognosis among Hospitalized Cirrhotic Patients with Spontaneous Bacterial Peritonitis
下载PDF
导出
摘要 目的 探讨肝硬化腹水患者医院感染自发性腹膜炎 (SBP)后肾功能的变化及其与预后的关系。方法 观察 162例医院感染 SBP患者的肾功能的变化 ,分析肾功能损害 (RI)的演变过程与死亡率的关系。结果 有 SBP的患者肾功能损害 (SBP-RI)发生率明显高于无 SBP患者肾功能损害发生率 (P<0 .0 0 1) ,63例发生 SBP-RI的患者中 ,进展型 SBP-RI占 3 6.5 1% ,稳定型 SBP-RI占 3 3 .3 3 % ,一过型 SBP-RI占 3 0 .16% ,进展型和稳定型 SBP-RI死亡率 (73 .91%、42 .86% )显著高于无 SBP-RI者 (16.16% ) ,一过型 SBP-RI(15 .79% )不增加死亡率。结论 SBP-RI的主要原因是感染 。 OBJECTIVE To study the changes in renal function in cirrhotic patients with spontaneous bacterial peritonitis(SBP) in hospital and to investigate the relationship between them and the patients′ prognosis. METHODS The changes in renal function and the relationship between renal impairment (RI) clinic course and mortality in 162 cirrhotic patients with SBP were analyzed. RESULTS The renal impairment incidence of cirrhotic patients with SBP (SBP RI) is significantly higher than that of patients without SBP (P<0.001). Among 63 patients occurred SBP RI, 36.51% patients are with progressive SBP RI, 33.33% with steady one and 30.16% with transient one. The mortality of progressive and steady SBP RI (73.91%, 42.86%) is significantly higher while the mortality of transient SBP RI (15.79%) is lesser than that of patients without SBP RI (16.16%). CONCLUSIONS The main cause of SBP RI is infection. The higher mortality of SBP RI has correlated with renal impairment.
出处 《中华医院感染学杂志》 CAS CSCD 2002年第9期658-659,共2页 Chinese Journal of Nosocomiology
关键词 肝硬化 自发性腹膜炎 肾功能损害 预后 SBP Cirrhosis Spontaneous bacterial peritonitis Renal impairment Prognosis
  • 相关文献

参考文献1

二级参考文献6

共引文献12

同被引文献32

  • 1黄桂连.肝硬化并发自发性腹膜炎血清胆红素及肾功能的变化与预后的关系[J].湖南师范大学学报(医学版),2005,2(1):75-76. 被引量:2
  • 2曹晓红,马巍,汤连志.重症监护病房医院感染的分析及护理措施[J].中华医院感染学杂志,2005,15(2):179-180. 被引量:70
  • 3陈自平,卢圣爱,徐昌青,刘倩,杜宗玫.重型病毒性肝炎患者医院感染及其预防[J].中华医院感染学杂志,2005,15(7):790-791. 被引量:19
  • 4Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association.肝衰竭诊疗指南[J].中华肝脏病杂志,2006,14(9):643-646. 被引量:829
  • 5[1]Johnson MA, Horak J, Breuel P. The pharmacokinetics of lamivudine in patients with impaired hepatic function[J]. Eur J Clin Pharmacol, 1998, 54(4): 363-366.
  • 6[3]Yamamura Y, Tanaka N. The relationship between pharmacokinetic behaviour of glycyrrhizin and hepatitis and liver cirrhosis[J]. Biopharm Drug Dispos, 1995, 16(1): 13-21.
  • 7Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis [ J ] . Gut, 2007, 56 (9): 1310-1318.
  • 8Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis : an update [ J ] . Hepatology, 2009, 49 ( 6 ) : 2087-2107.
  • 9Kashani A, Landaverde C, Medici V, et al. Fluid retention in cirrhosis : pathophysiology and management [ J ] . QJM, 2008, 101 (2) : 71-85.
  • 10郑月红.病毒性肝炎医院感染31例分析.中华医院感染学杂志,2001,11(3):228-228.

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部